Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 16Cyclophosphamide 12fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Vincristine 5Radiotherapy 5Prednisone 5Lenalidomide 5Etoposide 5Doxorubicin 5Cytarabine 5Bendamustine Hydrochloride 5fludarabine 4Whole-Body Irradiation 4Filgrastim 4tazemetostat 3Mycophenolic Acid 3Melphalan 3Carmustine 3umbralisib 2ublituximab 2sargramostim 2parsaclisib 2ofatumumab 2ibritumomab tiuxetan 2duvelisib 2Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Follicular × EPOCH protocol × Clear all
NCT00006669 2021-10-27

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Medstar Health Research Institute

Phase 2 Withdrawn
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡